BACKGROUND:Agitation is one of the most common neuropsychiatric symptoms of Alzheimer's disease (AD), and is associated with serious adverse consequences for patients and caregivers. Evidence-supported treatment options for agitation are limited. The citalopram for agitation in Alzheimer's disease (CitAD) study was designed to evaluate the potential of citalopram to ameliorate these symptoms. METHODS: CitAD is a randomized, double-masked, placebo-controlled multicenter clinical trial, with two parallel treatment groups assigned in a 1:1 ratio and randomization stratified by clinical center. The study included eight recruiting clinical centers, a chair's office, and a coordinating center located in university settings in the United States and Canada. A total of 200 individuals having probable AD with clinically significant agitation and without major depression were recruited for this study. Patients were randomized to receive citalopram (target dose of 30 mg/d) or matching placebo. Caregivers of patients in both treatment groups received a structured psychosocial therapy. Agitation was compared between treatment groups using the NeuroBehavioral Rating Scale and the AD Cooperative Study- Clinical Global Impression of Change, which are the primary outcomes. Functional performance, cognition, caregiver distress, and rates of adverse and serious adverse events were also measured. CONCLUSION: The authors believe the design elements in CitAD are important features to be included in trials assessing the safety and efficacy of psychotropic medications for clinically significant agitation in AD. Copyright Â
RCT Entities:
BACKGROUND:Agitation is one of the most common neuropsychiatric symptoms of Alzheimer's disease (AD), and is associated with serious adverse consequences for patients and caregivers. Evidence-supported treatment options for agitation are limited. The citalopram for agitation in Alzheimer's disease (CitAD) study was designed to evaluate the potential of citalopram to ameliorate these symptoms. METHODS:CitAD is a randomized, double-masked, placebo-controlled multicenter clinical trial, with two parallel treatment groups assigned in a 1:1 ratio and randomization stratified by clinical center. The study included eight recruiting clinical centers, a chair's office, and a coordinating center located in university settings in the United States and Canada. A total of 200 individuals having probable AD with clinically significant agitation and without major depression were recruited for this study. Patients were randomized to receive citalopram (target dose of 30 mg/d) or matching placebo. Caregivers of patients in both treatment groups received a structured psychosocial therapy. Agitation was compared between treatment groups using the NeuroBehavioral Rating Scale and the AD Cooperative Study- Clinical Global Impression of Change, which are the primary outcomes. Functional performance, cognition, caregiver distress, and rates of adverse and serious adverse events were also measured. CONCLUSION: The authors believe the design elements in CitAD are important features to be included in trials assessing the safety and efficacy of psychotropic medications for clinically significant agitation in AD. Copyright Â
Authors: Pauline Aalten; Marjolein E de Vugt; Niek Jaspers; Jaspers Jolles; Frans R J Verhey Journal: Int J Geriatr Psychiatry Date: 2005-06 Impact factor: 3.485
Authors: Clive Ballard; Marisa Margallo-Lana; Edmund Juszczak; Simon Douglas; Alan Swann; Alan Thomas; John O'Brien; Anna Everratt; Stuart Sadler; Clare Maddison; Lesley Lee; Carol Bannister; Ruth Elvish; Robin Jacoby Journal: BMJ Date: 2005-02-18
Authors: A L Nyth; C G Gottfries; K Lyby; L Smedegaard-Andersen; J Gylding-Sabroe; M Kristensen; H E Refsum; E Ofsti; S Eriksson; S Syversen Journal: Acta Psychiatr Scand Date: 1992-08 Impact factor: 6.392
Authors: Frédéric Assal; Maricela Alarcón; Esther C Solomon; Donna Masterman; Daniel H Geschwind; Jeffrey L Cummings Journal: Arch Neurol Date: 2004-08
Authors: Paul B Rosenberg; Krista L Lanctôt; Lea T Drye; Nathan Herrmann; Roberta W Scherer; David L Bachman; Jacobo E Mintzer Journal: J Clin Psychiatry Date: 2013-08 Impact factor: 4.384
Authors: Zahinoor Ismail; Eric E Smith; Yonas Geda; David Sultzer; Henry Brodaty; Gwenn Smith; Luis Agüera-Ortiz; Rob Sweet; David Miller; Constantine G Lyketsos Journal: Alzheimers Dement Date: 2015-06-18 Impact factor: 21.566
Authors: Ye Tao; Matthew E Peters; Lea T Drye; Davangere P Devanand; Jacobo E Mintzer; Bruce G Pollock; Anton P Porsteinsson; Paul B Rosenberg; Lon S Schneider; David M Shade; Daniel Weintraub; Jerome Yesavage; Constantine G Lyketsos; Cynthia A Munro Journal: Am J Alzheimers Dis Other Demen Date: 2018-07-03 Impact factor: 2.035
Authors: Anton P Porsteinsson; Lea T Drye; Bruce G Pollock; D P Devanand; Constantine Frangakis; Zahinoor Ismail; Christopher Marano; Curtis L Meinert; Jacobo E Mintzer; Cynthia A Munro; Gregory Pelton; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; David M Shade; Daniel Weintraub; Jerome Yesavage; Constantine G Lyketsos Journal: JAMA Date: 2014-02-19 Impact factor: 56.272
Authors: Jeffery Newell; Jerome A Yesavage; Joy L Taylor; Helena C Kraemer; Cynthia A Munro; Leah Friedman; Paul B Rosenberg; Michelle Madore; Steven Z Chao; D P Devanand; Lea T Drye; Jacobo E Mintzer; Bruce G Pollock; Anton P Porsteinsson; Lon S Schneider; David M Shade; Daniel Weintraub; Constantine G Lyketsos; Art Noda Journal: J Psychiatr Res Date: 2015-12-12 Impact factor: 4.791
Authors: Dimitris N Kiosses; Paul B Rosenberg; Amanda McGovern; Pasquale Fonzetti; Hana Zaydens; George S Alexopoulos Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Paul B Rosenberg; Lea T Drye; Anton P Porsteinsson; Bruce G Pollock; D P Devanand; Constantine Frangakis; Zahinoor Ismail; Christopher Marano; Curtis L Meinert; Jacobo E Mintzer; Cynthia A Munro; Gregory Pelton; Peter V Rabins; Lon S Schneider; David M Shade; Daniel Weintraub; Jeffery Newell; Jerome Yesavage; Constantine G Lyketsos Journal: Int Psychogeriatr Date: 2015-08-25 Impact factor: 3.878